🔎 Trials Near Me

Pradžia › Mezotelioma › Tennessee

Mezotelioma klinikiniai tyrimai Tennessee

8 tyrimai dėl Mezotelioma ieško dalyvių vietose Tennessee.

Miestai Tennessee

Oficialus tyrimo tekstas (anglų kalba)

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • Sarah Cannon Research Institute, Nashville
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT07277413

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Vanderbilt University Medical Center, Nashville
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT04981119

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

  • SCRI Oncology Partners, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT06566079

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

  • Sarah Cannon Tennessee Oncology, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT05732831

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

  • Vanderbilt - Ingram Cancer Center, Nashville
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT05245500

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Sarah Cannon Research Institute at Tennessee Oncology, Nashville
  • Tennessee Oncology, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT05579366

CT-95 in Advanced Cancers Associated With Mesothelin Expression

  • Context Investigational Site, Nashville
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-12 · NCT06756035

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • Vanderbilt University Medical Center, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-12 · NCT06051695

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.